Accelerated treatment regimen feasible for advanced NSCLC -
Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).
Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation -
Scientists have identified four new genes associated with the severe food allergy eosinophilic esophagitis (EoE). Because the genes appear to have roles in other allergic diseases and in inflammation, the findings may point toward potential new treatments for EoE.
Promising molecular diagnostic approach to endometriosis -
EDDA Technology, a global leading provider in advanced real-time interactive quantitative imaging solutions, announced today that the company has received FDA clearance on IQQA-BodyImaging.
2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone) -
A study by a Wayne State University and Children's Hospital of Michigan, Detroit Medical Center research team is shedding new light on the troubling question of whether the drugs often given to HIV-positive pregnant women can cause significant long-term heart problems for the non-HIV-infected babies they carry.
Investigational drug maintains normal potassium levels in patients with chronic kidney disease -
Women with symptoms of serious mental illness are significantly less likely to receive three routine cancer screenings - Pap tests, mammograms and clinical breast exams - than women in the general population, despite being at elevated risk for medical comorbidities and early death, a new study indicates.